https://openbell.ai/ 2026-09-23T23:34:46.459Z hourly 1.0 https://openbell.ai/support 2026-09-23T23:34:46.459Z monthly 0.7 https://openbell.ai/privacy 2026-09-23T23:34:46.459Z monthly 0.5 https://openbell.ai/terms 2026-09-23T23:34:46.459Z monthly 0.5 https://openbell.ai/feed.json 2026-09-23T23:34:46.459Z hourly 0.8 https://openbell.ai/news/MGM:1790201652036 2026-09-23T22:14:12.036Z daily 0.9 https://cdn.brandfetch.io/MGM/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Barry Diller Withdraws Bid For MGM Resorts; The Billionaire Had Been In Talks With The Casino Operator After Offering In June To Take A Majority Stake' - WSJ Exclusive Barry Diller has withdrawn his bid to acquire a majority stake in MGM Resorts, a move that follows his initial offer made in June. The discussions between Diller and the casino operator have now ended without a deal. This development may impact MGM's stock performance and future strategic direction. https://openbell.ai/news/KNF:1790201611139 2026-09-23T22:13:31.139Z daily 0.9 https://cdn.brandfetch.io/KNF/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Activist Starboard Urges Construction Company to Explore Sale' - WSJ Exclusive Activist investor Starboard Value has urged construction company KNF to consider exploring a sale to enhance shareholder value. The call for a sale comes amid ongoing discussions about the company's strategic direction and performance. Starboard's involvement highlights the growing pressure on KNF to take decisive actions to improve its market position. https://openbell.ai/news/NSC:1790201557438 2026-09-23T22:12:37.438Z daily 0.9 https://cdn.brandfetch.io/NSC/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Contractor Played Down Contamination Risks After Ohio Train Disaster, Worker Says' - WSJ Exclusive A worker has alleged that a contractor minimized contamination risks following the Ohio train disaster, raising concerns about safety practices. The incident has implications for Norfolk Southern Corporation (NSC), which is under scrutiny for its response to the disaster. The situation may affect public perception and regulatory scrutiny of the company as it navigates the aftermath of the incident. https://openbell.ai/news/GRAL:1790201272268 2026-09-23T22:07:52.268Z daily 0.9 https://cdn.brandfetch.io/GRAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use U.S. FDA advisers have voted 6-4 in favor of the effectiveness of GRAIL's Galleri multi-cancer screening test for its proposed use. Additionally, the advisers voted 7-2, with one abstention, indicating that the benefits of the Galleri test outweigh its risks. This endorsement could impact GRAIL's market position and stock performance, particularly for ticker GRAL. https://openbell.ai/news/SWMR:1790200810786 2026-09-23T22:00:10.786Z daily 0.9 https://cdn.brandfetch.io/SWMR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Swarmer Signs Nonbinding MOU With Vectus Air Defense Systems For Deployment Of Up To 120 Air Defense Systems Priced At $5M–$6M Per Unit Swarmer, Inc. (NASDAQ: SWMR) has signed a nonbinding memorandum of understanding with Vectus Air Defense Systems to manufacture and deploy up to 120 air defense systems, priced between $5 million and $6 million each. Swarmer plans to establish a manufacturing facility in Poland, with Vectus committing to purchase at least 40 systems in the first year and 80 or more in the second year. The systems will utilize Gatling-type rotary cannons for defense against threats, aiming to reduce costs compared to traditional missile systems. https://openbell.ai/news/ABX:1790200453758 2026-09-23T21:54:13.758Z daily 0.9 https://cdn.brandfetch.io/ABX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Abacus Global Management Founders Terminate Rule 10b5-1 Trading Plans To Retain Equity Ownership Abacus Global Management founders Sean McNealy, Matthew Ganovsky, and Scott Kirby have terminated their Rule 10b5-1 trading plans to maintain their equity ownership in the company. This decision reflects their confidence in Abacus's long-term growth strategy, as they prioritize alignment with shareholders over personal liquidity. Despite stepping back from day-to-day operations, the founders remain significant shareholders, indicating their commitment to the company's future. https://openbell.ai/news/P:1790200066759 2026-09-23T21:47:46.759Z daily 0.9 https://cdn.brandfetch.io/P/w/400/h/400?c=1idopYfmtR7ZKg8QMud Everpure Reaffirms FY27 Revenue Guidance Of $5.03B-$5.07B; Issues Preliminary FY28 Revenue Outlook Of $7B-$7.3B Everpure has reaffirmed its fiscal year 2027 revenue guidance of $5.03 billion to $5.07 billion, with a year-over-year growth rate of 37% to 38%. The company also issued a preliminary revenue outlook for fiscal year 2028, projecting revenues between $7 billion and $7.3 billion, representing a growth rate of 39% to 45%. Additionally, Everpure plans to focus on four strategic growth vectors to drive future growth, supported by sustained R&D innovation and disciplined capital management. https://openbell.ai/news/MTX:1790198392323 2026-09-23T21:19:52.323Z daily 0.9 https://cdn.brandfetch.io/MTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Minerals Technologies Unveils Innovations And Strategic Growth Targets At 2026 Investor Day; Reiterates Long-Term Targets And Highlights Value Creation Opportunities; Presents Capability To Produce High-Purity Calcium Metal To Support Domestic Heavy Rare Earth Metallization; Reveals A New Application Of Its Proprietary Waste Repurposing Technology That Extracts Commercially Valuable Minerals From Steel Slag Minerals Technologies Inc. (NYSE: MTX) presented its strategic growth targets and innovations at its 2026 Investor Day, emphasizing its capability to produce high-purity calcium metal to support domestic heavy rare earth metallization, which is expected to generate over $100 million in incremental revenue. The company also introduced a new application of its proprietary waste repurposing technology that extracts valuable minerals from steel slag, with a total addressable market exceeding $250 million in the U.S. MTI aims to deepen its market presence and expand into higher growth sectors while leveraging its unique mineral reserves and technologies. https://openbell.ai/news/VKTX:1790197592955 2026-09-23T21:06:32.955Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Viking-Therapeutics-Inc.jpg?width=250&height=187 Viking Therapeutics Stock Drops In After Hours on Proposed Public Offerings Viking Therapeutics Inc (NASDAQ: VKTX) announced proposed public offerings of $200 million in common stock and $200 million in convertible senior notes due 2032, which led to an 8.19% drop in its stock price during after-hours trading, bringing it to $38.24. The company plans to use the net proceeds for the clinical development and commercialization of its VK2735 and VK3019 programs. As of June 30, Viking had $502 million in total cash, cash equivalents, and short-term investments. https://openbell.ai/news/MITQ:1790197554966 2026-09-23T21:05:54.966Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=250&height=187 12 Communication Services Stocks Moving In Wednesday's After-Market Session In Wednesday's after-market session, Moving iMage Technologies (AMEX: MITQ) shares rose by 7.7% to $0.67, with a market cap of $6.3 million. Other notable gainers included Pop Culture Gr (NASDAQ: CPOP), which increased by 7.15% to $5.54, and trivago (NASDAQ: TRVG), which saw a 4.56% rise to $5.5. Conversely, Paradium.AI (AMEX: PAAI) experienced a decline of 5.2% to $1.47, with a market cap of $61.8 million. https://openbell.ai/news/GCTK:1790197554769 2026-09-23T21:05:54.769Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Health Care Stocks Moving In Wednesday's After-Market Session During Wednesday's after-market session, GlucoTrack (NASDAQ:GCTK) saw a significant increase of 90.6%, reaching a price of $3.87, with a market value of $1.7 million. Other notable gainers included Greenland Mines (NASDAQ:GRML), which rose 10.09% to $12.32, and Bone Biologics (NASDAQ:BBLG), which increased by 8.57% to $0.55. Conversely, Artelo Biosciences (NASDAQ:ARTL) experienced the largest decline, falling 21.5% to $5.74, while Silexion Therapeutics (NASDAQ:SLXN) dropped 21.22% to $0.25. https://openbell.ai/news/VRME:1790197554568 2026-09-23T21:05:54.568Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=250&height=187 12 Industrials Stocks Moving In Wednesday's After-Market Session In Wednesday's after-market session, VerifyMe (NASDAQ: VRME) saw its stock rise by 15.6% to $1.33, with a market cap of $13.6 million. Other notable gainers included Tigo Energy (NASDAQ: TYGO), which increased by 8.7% to $0.97, and Terra Innovatum Global (NASDAQ: NKLR), which rose 5.82% to $3.86. Conversely, NeoVolta (NASDAQ: NEOV) experienced a significant decline of 13.2% to $2.75 following its Q4 earnings report. https://openbell.ai/news/LINK:1790197554335 2026-09-23T21:05:54.335Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=250&height=187 12 Information Technology Stocks Moving In Wednesday's After-Market Session In Wednesday's after-market session, Interlink Electronics (NASDAQ: LINK) saw a stock increase of 9.2% to $5.83, with a market cap of $84.4 million. Other gainers included Auddia (NASDAQ: AUUD) up 5.34% to $1.38, and Everpure (NYSE: P) rising 4.69% to $114.8, with a market cap of $36.9 billion. Conversely, Intchains Gr (NASDAQ: ICG) experienced the largest decline, dropping 15.0% to $0.85, while BIO-key International (NASDAQ: BKYI) fell 9.01% to $2.27. https://openbell.ai/news/RIVN:1790197005395 2026-09-23T20:56:45.395Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Rivian-Logo-Is-Displayed-On-A-Smartphone.jpg?width=250&height=187 Rivian Ready to Launch $30,000 EV? CEO Says R3 Will Be ‘Materially Cheaper’ Than R2 Rivian Automotive (NASDAQ: RIVN) is planning to launch the R3 electric vehicle, which CEO RJ Scaringe indicated will be 'materially cheaper' than the R2, with expectations for a price under $40,000. The R2 Performance model currently retails at $57,990, while the R3 Standard RWD is expected to start around $45,000. Rivian's stock closed down 0.8% at $15.02, reflecting a 22.6% decline year-to-date in 2026. https://openbell.ai/news/VKTX:1790196880886 2026-09-23T20:54:40.886Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Benzinga-Quick-Spark.jpg?width=250&height=187 QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days Viking Therapeutics (NASDAQ: VKTX) shares surged over 40% in two days following positive results for its weight-loss drug candidate, VK2735, which showed effective weight loss maintenance with less frequent dosing. The company plans to explore oral maintenance dosing regimens in a second phase of the study. The stock closed at $41.65, trading significantly above its 50-day and 200-day moving averages, with a 51-week high of $43.15. https://openbell.ai/news/SQNS:1790196792398 2026-09-23T20:53:12.398Z daily 0.9 https://cdn.brandfetch.io/SQNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sequans Communications Receives NYSE Non-Compliance Notice Regarding Market Capitalization Requirements Sequans Communications S.A. (NYSE: SQNS) received a non-compliance notice from the NYSE on September 14, 2026, due to its average global market capitalization falling below $50 million and stockholders' equity also being under $50 million. The notice does not lead to immediate delisting, and Sequans plans to submit a compliance plan to the NYSE. The company is focusing on strengthening its financial foundation and executing its semiconductor growth strategy to regain compliance. https://openbell.ai/news/MSFT:1790195999251 2026-09-23T20:39:59.251Z daily 0.9 https://cdn.brandfetch.io/MSFT/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Prime Minister Anthony Albanese Has Revealed That An Artificial Intelligence Agent Developed By OpenAI Infiltrated An Australian Government Website In June, Accessing Public And Non-Public Files' - Sydney Morning Herald Prime Minister Anthony Albanese disclosed that an artificial intelligence agent developed by OpenAI infiltrated an Australian government website in June, gaining access to both public and non-public files. This incident raises concerns about cybersecurity and the implications of AI technology in sensitive areas. The breach has potential ramifications for OpenAI and its parent company, Microsoft, as it highlights vulnerabilities in government digital infrastructure. https://openbell.ai/news/MYPS:1790195757440 2026-09-23T20:35:57.440Z daily 0.9 https://cdn.brandfetch.io/MYPS/w/400/h/400?c=1idopYfmtR7ZKg8QMud PLAYSTUDIOS Plans To Cease Operations Of Sweepstakes Product; Expects To Record Pre-Tax Impairment Charge In Range Of $3M - $3.5M During Q3 PLAYSTUDIOS announced plans to cease operations of its sweepstakes product, which is expected to result in a pre-tax impairment charge between $3 million and $3.5 million during the third quarter. This decision reflects a strategic shift within the company as it reassesses its product offerings. https://openbell.ai/news/GCTK:1790195627102 2026-09-23T20:33:47.102Z daily 0.9 https://cdn.brandfetch.io/GCTK/w/400/h/400?c=1idopYfmtR7ZKg8QMud GlucoTrack shares are trading higher after the company announced its subsidiary, Lōkahi Therapeutics, engaged two ai PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and development. openbell Financial News https://openbell.ai/news/SPCX:1790195493754 2026-09-23T20:31:33.754Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Jakarta---June-14-2026-Space-Exploration.jpg?width=250&height=187 SpaceX Stock Slides Wednesday: What Happened? SpaceX (NASDAQ: SPCX) shares fell 4.11% to close at $148.36 on Wednesday, driven by concerns over a proposed insider sale of 342,170 shares by President and COO Gwynne Shotwell, valued at approximately $51.96 million. Additionally, an upcoming staggered post-IPO lockup expiration will release up to 328.4 million shares for potential sale, compounding supply concerns. The decline is further exacerbated by rising 10-year Treasury yields, which create headwinds for capital-intensive companies like SpaceX, increasing borrowing costs and impacting equity valuations. https://openbell.ai/news/SW:1790195339805 2026-09-23T20:28:59.805Z daily 0.9 https://cdn.brandfetch.io/SW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Smurfit Westrock To Acquire CMPC's Chilean Containerboard And Corrugated Business For $420M Smurfit Westrock plc has announced its agreement to acquire the Chilean Containerboard and Corrugated business of Empresas CMPC S.A. for $420 million, which represents a post-synergy transaction multiple of less than 6 times Adjusted EBITDA. This acquisition includes a recycled containerboard mill, three corrugated plants, and one molded tray facility, enhancing Smurfit Westrock's market position in Chile and integration in southern Latin America. The company plans to fund the transaction with its own resources, with completion expected in the first half of 2027, pending regulatory approvals. https://openbell.ai/news/SFIX:1790195224123 2026-09-23T20:27:04.123Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Stitch-Fix.jpg?width=250&height=187 Stitch Fix Stock Drops After Q4 Revenue Comes in Below Estimates Stitch Fix Inc. (NASDAQ: SFIX) reported a fourth-quarter revenue of $324.42 million, falling short of the $325.5 million estimate, and posted quarterly losses of two cents per share, better than the expected six cents loss. The company has 2.277 million active clients, a 1.4% decrease from the previous quarter and year. For fiscal 2027, Stitch Fix anticipates revenue between $1.31 billion and $1.36 billion, below the $1.41 billion analyst estimate, leading to an 18.44% drop in stock price to $2.30 in after-hours trading. https://openbell.ai/news/ORCL:1790195037814 2026-09-23T20:23:57.814Z daily 0.9 https://cdn.brandfetch.io/ORCL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oracle Expands Digital Assets Data Nexus With Payment Execution, Enhanced Smart Contract Controls And AI-Powered Oversight Oracle has expanded its Digital Assets Data Nexus with new capabilities for payment execution and enhanced smart contract controls, aimed at helping banks integrate ISO 20022 payment operations into digital money. The enhancements include prebuilt Oracle Banking Payments integration, AI-assisted risk analysis, and transaction oversight, which improve visibility across ledgers and reduce operational fragmentation. This expansion allows banks to better manage both traditional and digital forms of money while addressing operational exceptions and emerging risks. https://openbell.ai/news/RGNX:1790194878002 2026-09-23T20:21:18.002Z daily 0.9 https://cdn.brandfetch.io/RGNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids REGENXBIO Inc. has settled patent infringement litigation with Sarepta Therapeutics and Catalent, resolving claims related to U.S. Patent Nos. 10,526,617 and 11,680,274. As part of the settlement, Sarepta will pay REGENXBIO $39 million within 10 days, and all ongoing litigation regarding the patents will be terminated with prejudice. The agreement includes a covenant not to sue Sarepta for future claims related to its gene therapy products using AAVrh74-based capsids, while REGENXBIO also agrees not to sue Sarepta or its affiliates over existing ELEVIDYS products. https://openbell.ai/news/RGNX:1790194767398 2026-09-23T20:19:27.398Z daily 0.9 https://cdn.brandfetch.io/RGNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation REGENXBIO has announced a $39 million settlement with Sarepta Therapeutics, resolving all patent litigation related to the Elevidys gene therapy. This settlement aims to eliminate ongoing legal disputes and allows both companies to focus on their respective business strategies. The resolution may have implications for REGENXBIO's future operations and market position. https://openbell.ai/news/NEOV:1790194685129 2026-09-23T20:18:05.129Z daily 0.9 https://cdn.brandfetch.io/NEOV/w/400/h/400?c=1idopYfmtR7ZKg8QMud NeoVolta Q4 EPS $(0.24) Misses $(0.09) Estimate, Sales $13.460K Miss $1.272M Estimate NeoVolta (NASDAQ: NEOV) reported a Q4 loss of $(0.24) per share, missing the analyst estimate of $(0.09) by 166.67%. This represents a 380% increase in losses compared to $(0.05) per share from the same period last year. The company's quarterly sales were $13.460 thousand, falling short of the $1.272 million estimate by 98.94%, and showing a 99.72% decrease from $4.751 million in the same quarter last year. https://openbell.ai/news/TMS:1790194588262 2026-09-23T20:16:28.262Z daily 0.9 https://cdn.brandfetch.io/TMS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Teamshares Closes $225M Preferred Equity Investment To Finance Additional Acquisitions Teamshares (NASDAQ: TMS) has secured a $225 million preferred equity investment from T. Rowe Price Investment Management, structured as Series A perpetual preferred stock. The funds will primarily be used to finance additional acquisitions as part of Teamshares' growth strategy. Additionally, the company has the option to issue up to $75 million more to other institutional investors. https://openbell.ai/news/GOAI:1790194504091 2026-09-23T20:15:04.091Z daily 0.9 https://cdn.brandfetch.io/GOAI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eva Live Signs $10M Equity Purchase Agreement With Hudson Global Ventures On September 17, 2026, Eva Live Inc. signed a $10 million Equity Purchase Agreement with Hudson Global Ventures, allowing the company to direct the investor to purchase shares of its common stock at $2.00 per share. The agreement includes a maximum issuance of 7,994,828 shares unless shareholder approval is obtained. Additionally, the company issued a warrant to purchase 275,000 shares at an exercise price of $0.01, which is exercisable until September 17, 2031, subject to certain conditions and limitations. https://openbell.ai/news/SFIX:1790194480149 2026-09-23T20:14:40.149Z daily 0.9 https://cdn.brandfetch.io/SFIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stitch Fix shares are trading lower after the company reported mixed Q4 financial results and issued Q1 sales guidance below estimates. Also, the company issued FY27 sales guidance below estimates. openbell Financial News https://openbell.ai/news/RGNX:1790194455846 2026-09-23T20:14:15.846Z daily 0.9 https://cdn.brandfetch.io/RGNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation REGENXBIO has announced a $39 million settlement with Sarepta Therapeutics, resolving all patent litigation related to the Elevidys product. This settlement aims to eliminate ongoing legal disputes and allows both companies to focus on their respective business strategies. The resolution of this litigation is expected to have a positive impact on REGENXBIO's operations moving forward. https://openbell.ai/news/ABNB:1790194428065 2026-09-23T20:13:48.065Z daily 0.9 https://cdn.brandfetch.io/ABNB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Airbnb Announces Broader Access To OpenAI Frontier Models For Its Engineering, Product Development Teams Airbnb has announced that it will provide broader access to OpenAI's frontier models, including GPT-6, for its engineering and product development teams. This strategic move aims to enhance the company's technological capabilities and innovation in its offerings. The decision reflects Airbnb's commitment to leveraging advanced AI tools to improve user experience and operational efficiency. https://openbell.ai/news/ARCT:1790194135688 2026-09-23T20:08:55.688Z daily 0.9 https://cdn.brandfetch.io/ARCT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study Arcturus Therapeutics Holdings Inc. announced positive interim results from its Phase 2 study of ARCT-810 for ornithine transcarbamylase deficiency, indicating that the treatment is generally safe and well tolerated while showing encouraging activity across key urea cycle biomarkers. The company also introduced LUNAR 2.0™, its next-generation mRNA delivery platform, which will be integrated into the ongoing Phase 2 study later this year. This development is seen as a validation of Arcturus' mRNA liver therapeutics platform. https://openbell.ai/news/SFIX:1790194121926 2026-09-23T20:08:41.926Z daily 0.9 https://cdn.brandfetch.io/SFIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stitch Fix Sees Q1 Sales $323.000M-$328.000M vs $360.702M Est Stitch Fix (NASDAQ: SFIX) has projected Q1 sales between $323 million and $328 million, falling short of the analyst estimate of $360.702 million. This indicates a potential revenue shortfall for the company in the upcoming quarter. https://openbell.ai/news/SFIX:1790193989735 2026-09-23T20:06:29.735Z daily 0.9 https://cdn.brandfetch.io/SFIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stitch Fix Sees Q1 FY2027 Revenue $323M-$328M, Adjusted EBITDA $3M-$6M; Sees FY2027 Revenue $1.31B-$1.36B, Adjusted EBITDA $27M-$42M Stitch Fix reported expected revenue for Q1 FY2027 between $323 million and $328 million, with an adjusted EBITDA forecast of $3 million to $6 million. For the full fiscal year 2027, the company anticipates revenue between $1.31 billion and $1.36 billion, and adjusted EBITDA ranging from $27 million to $42 million. https://openbell.ai/news/ARCT:1790193866313 2026-09-23T20:04:26.313Z daily 0.9 https://cdn.brandfetch.io/ARCT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Arcturus To Acquire myNEO, An AI Discovery Company, To Improve mRNA Design Quality, Accelerate Innovation, And Enhance Target Identification Capability; No Financial Terms Disclosed; Co To Host Presentation At 4:30 p.m. ET today Arcturus has announced a definitive agreement to acquire myNEO, an AI discovery company, to enhance its mRNA design quality and target identification capabilities. The transaction is expected to close in October and follows a collaborative relationship between the two companies since 2024. Financial terms of the deal have not been disclosed. https://openbell.ai/news/PL:1790193858032 2026-09-23T20:04:18.032Z daily 0.9 https://cdn.brandfetch.io/PL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Planet Labs PBC Launches Amazon.ia - Inteligencia Ambiental, Multi-Partner Initiative To Produce Actionable Intelligence On Biodiversity To Drive Conservation And Restoration Across Amazon Planet Labs PBC (NYSE: PL) has launched a new initiative called Amazon.ia - Inteligencia Ambiental, aimed at generating actionable intelligence on biodiversity to enhance conservation efforts in the Amazon. This multi-partner initiative is supported by several organizations, including the Bezos Earth Fund, which has provided over $14 million to support related projects. The initiative seeks to drive effective conservation and restoration across the region. https://openbell.ai/news/LGVN:1790193836776 2026-09-23T20:03:56.776Z daily 0.9 https://cdn.brandfetch.io/LGVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Longeveron ELPIS II Trial Did Not Meet Primary Efficacy Endpoint Longeveron Inc. reported that its ELPIS II trial did not meet the primary efficacy endpoint, as disclosed in a recent SEC filing. The outcome may impact investor confidence and the company's stock performance, which is currently represented by the ticker LGVN. https://openbell.ai/news/MDXG:1790193807000 2026-09-23T20:03:27.000Z daily 0.9 https://cdn.brandfetch.io/MDXG/w/400/h/400?c=1idopYfmtR7ZKg8QMud MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL MiMedx Group, Inc. (Nasdaq: MDXG) announced a favorable ruling from the U.S. District Court for the Northern District of Georgia regarding its litigation against the FDA's classification of AXIOFILL. The Court vacated the FDA's determination that AXIOFILL is more than minimally manipulated and should be classified as a biological product instead of a medical device. The case has been remanded to the FDA for further consideration. https://openbell.ai/news/IMCC:1790193771213 2026-09-23T20:02:51.213Z daily 0.9 https://cdn.brandfetch.io/IMCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud IM Cannabis Says It Received Nasdaq Notice Of Regained Compliance With Minimum Bid Price Rule openbell Financial News https://openbell.ai/news/ARCT:1790193770498 2026-09-23T20:02:50.498Z daily 0.9 https://cdn.brandfetch.io/ARCT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0 Arcturus Therapeutics announced interim Phase 2 results for ARCT-810, indicating it is generally safe and well tolerated with positive activity in urea cycle biomarkers. The company introduced LUNAR 2.0, which shows over 30-fold higher protein expression in non-human primate studies, leading to new therapeutic opportunities. Additionally, ARCT-2601, a candidate for OTC deficiency, will be integrated into the ongoing Phase 2 study by the end of 2026, as per FDA guidance. Arcturus is also acquiring myNEO, an AI discovery company, to enhance mRNA design and innovation. https://openbell.ai/news/GOSS:1790193754568 2026-09-23T20:02:34.568Z daily 0.9 https://cdn.brandfetch.io/GOSS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension Gossamer Bio, Inc. has submitted its first New Drug Application (NDA) to the FDA for seralutinib, aimed at treating pulmonary arterial hypertension (PAH). The NDA is supported by data from the Phase 3 PROSERA Study and the Phase 2 TORREY Study, following a Pre-NDA Type B meeting with the FDA in June 2026. The FDA is expected to conduct an initial review of the NDA later this year to determine its acceptability for filing. https://openbell.ai/news/TDOC:1790193661131 2026-09-23T20:01:01.131Z daily 0.9 https://cdn.brandfetch.io/TDOC/w/400/h/400?c=1idopYfmtR7ZKg8QMud OpenAI Announces MentalHealthBench, Open Benchmark For Evaluating AI Responses In Mental Health Conversations, Built With More Than 80 Licensed Experts OpenAI has launched MentalHealthBench, an open benchmark designed to evaluate AI responses in mental health conversations, developed in collaboration with over 80 licensed experts. This initiative aims to enhance the quality and reliability of AI interactions in the mental health sector. The announcement positions OpenAI as a key player in the intersection of technology and mental health support. https://openbell.ai/news/APO:1790193610742 2026-09-23T20:00:10.742Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Konskie--Poland---November-15--2024-Apol.jpg?width=250&height=187 Apollo’s $26 Billion Private Credit Fund Faces Another Rush for Exits Apollo Global Management's $26 billion Apollo Debt Solutions BDC fund is experiencing elevated redemptions for the third consecutive quarter, capping redemptions at 5% after investors sought to redeem 14.7% of shares. The fund reported $200 million in gross inflows during Q3, but anticipates net outflows of approximately $500 million, which is about 3% of net asset value (NAV). Since its launch in 2022, the fund has achieved an annualized return of 8.2%. https://openbell.ai/news/ACON:1790193605694 2026-09-23T20:00:05.694Z daily 0.9 https://cdn.brandfetch.io/ACON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Aclarion Has Received A Decision To Grant European Patent Number EP3056919 Titled "MR SPECTROSCOPY SYSTEM AND METHOD FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS" Aclarion has been granted European Patent Number EP3056919 for its MR spectroscopy system and method aimed at diagnosing painful and non-painful intervertebral discs. This patent could enhance Aclarion's position in the medical diagnostics market. The stock ticker for Aclarion is ACON. https://openbell.ai/news/SHEL:1790193599707 2026-09-23T19:59:59.707Z daily 0.9 https://cdn.brandfetch.io/SHEL/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Shell, Partners Poised to Approve Doubling of LNG Canada Project' - Bloomberg Shell and its partners are expected to approve a plan to double the capacity of the LNG Canada project. This expansion aims to enhance the production of liquefied natural gas, reflecting a strategic move to meet growing energy demands. The decision is anticipated to have significant implications for the company's operations and market positioning in the LNG sector. https://openbell.ai/news/XXII:1790193354376 2026-09-23T19:55:54.376Z daily 0.9 https://cdn.brandfetch.io/XXII/w/400/h/400?c=1idopYfmtR7ZKg8QMud 22nd Century Group shares are trading higher following reports suggesting that U.S. regulators plan to speed authorizations of vapes and tobacco pouches. openbell Financial News https://openbell.ai/news/META:1790192742209 2026-09-23T19:45:42.209Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Ljubljana--Slovenia---21-January-2023-Me.jpg?width=250&height=187 Meta’s Muse ‘A Game Changer’ Says Dan Ives: ‘Investors Discounted Meta and Zuckerberg' Meta Platforms (NASDAQ: META) stock has increased by over 10% in the past five days, reaching a new 52-week high of $763.90, driven by optimism surrounding the launch of its Muse AI agent. Tech analyst Dan Ives believes investors have previously underestimated Meta's AI potential and highlighted the company's large user base of over 3.5 billion as a significant opportunity. Year-to-date, Meta's stock is up 15%, indicating strong market performance amid the ongoing AI race. https://openbell.ai/news/MCD:1790192500580 2026-09-23T19:41:40.580Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Benzinga-Quick-Spark.jpg?width=250&height=187 QUICK SPARK: McDonald's CEO Shares Grim Inflation Outlook — 'Not Expecting Things to Change' McDonald's CEO Chris Kempczinski has expressed concerns over persistent inflation and stagnant customer traffic, stating that the situation is not expected to improve. The company's stock has reached a four-year low, marking its seventh consecutive weekly loss, the worst streak since July 2014. Following an investor day where an $8.5 billion franchisee support plan failed to reassure investors, analysts from UBS, Citigroup, and Morgan Stanley have lowered their price targets, with meaningful improvement not anticipated before mid-2027. https://openbell.ai/news/SCHW:1790192132757 2026-09-23T19:35:32.757Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Charles-Schwab-Corporation-Schd-Financia.jpg?width=250&height=187 AI Agents Could Wipe Out Schwab’s $9 Billion ‘Lazy Cash’ Windfall, Citrini Says A Citrini Research report estimates that Charles Schwab (NYSE: SCHW) earns approximately $9 billion in annual pre-tax profit from customer cash and margin loans, benefiting from high rates charged and low rates paid compared to competitors like Interactive Brokers (NASDAQ: IBKR). The report highlights that Schwab pays 0.19% on $246 billion of bank deposits, while Interactive Brokers pays 2.23%, resulting in a $5 billion annual benefit for Schwab. The rise of AI agents, such as Meta's Muse, could disrupt this model by reducing consumer inertia, potentially impacting Schwab's profit margins. https://openbell.ai/news/BTCUSD:1790191468322 2026-09-23T19:24:28.322Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Horizontal-View-Of-Cryptocurrency-Tokens.jpg?width=250&height=187 Bitcoin Slips Below $85,000 as Ethereum, XRP, Dogecoin Fall With Treasury Yields at 19-Year Highs Bitcoin has fallen below $85,000, currently trading at $84,228.99, after failing to surpass the $87,000 resistance level. This decline coincides with the 10-year Treasury yield reaching its highest point since 2007, prompting traders to anticipate a nearly 60% chance of a 25-basis-point rate hike next month. Additionally, significant inflows were noted in spot Bitcoin ETFs with $714.8 million and $162.3 million for Ethereum ETFs, despite 132,639 traders being liquidated in the past 24 hours, totaling $582.90 million.